Delivery Order SPE2DB24D2013-SPE2DB25FCKBX
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $20,573.32. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is categorized as a child contract under AmerisourceBergen's broader federal contract portfolio. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Xifaxan 550 mg tablets in quantities of 60 units, with a contract ceiling value of $1,640.75. This firm fixed-price delivery order, which is not set-aside, is scheduled for ultimate completion on August 21, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order issued under...
- The Defense Logistics Agency awarded a delivery order valued at $25,366.11 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and is being performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. Xifaxan is a non-systemic antibiotic used primarily in the treatment of traveler's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) at a ceiling value of $1,846.22. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a contract value of $4,557.98. This firm fixed-price delivery order, with an ultimate completion date of July 30, 2025, represents a non-set-aside, competitively awarded procurement supporting federal medical supply needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) valued at $2,759.13. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents performance at the vendor's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating it was competitively awarded through open competition. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Xifaxan 550 mg tablets (60-count units) with a ceiling value of $28,942.08. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, was competitively awarded with no set-aside designation. The work will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company maintains operations as a...
- The Defense Logistics Agency awarded a delivery order valued at $12,991.41 to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) on August 20, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Xifaxan 550 mg tablets (60-count packages) under a firm fixed price contract valued at $4,888.67. This competitively awarded delivery order, with no set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a $14,427.52 delivery order to AmerisourceBergen Drug Corp for the supply of Xifaxan 550 mg tablets (60-count units) under a firm fixed-price contract structure. The award was made on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation. This contract represents a...
- SPE2DB24D2013Indefinite Delivery Contract
- SPE2DB24D2013-SPE2DB25FCKBXDelivery Order
The Defense Logistics Agency awarded a $43,495.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xifaxan 550 mg tablets (60-count units). The contract, which represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, carries an ultimate completion date of September 4, 2025, and involves no set-aside designation, indicating competitive award status. Performance will be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's comprehensive pharmaceutical supply agreement with DLA, valued at $999,999,999.00 through December 2026, which enables the company to provide a broad range of medications and medical supplies supporting military healthcare systems globally. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen maintains an extensive portfolio of contract awards with the Defense Logistics Agency covering diverse therapeutic domains. Xifaxan, a rifaxomicin-based antibiotic used primarily for traveler's diarrhea and hepatic encephalopathy, represents part of the company's specialized pharmaceutical offerings to support Defense Health Agency and other federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.5k | 9/3/25 |